This phase III trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant. The treatments used to prepare for HCT reduce the body's natural infection-fighting ability and increase the likelihood of an infection with a virus called cytomegalovirus. "Prophylaxis" means to take a drug to prevent a disease or side effect. Letermovir is an antiviral drug that stops cytomegalovirus from multiplying and may prevent cytomegalovirus infection and make the disease less severe. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact: IU Clinical Trials OfficeEmail: iutrials@iu.edu Phone: (317) 278-5632

The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass EliteTM with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.  THIS STUDY IS ENROLLING BY INVITATION ONLY - Subjects will initially be identified by physician/ provider referral or their medical records/ visit reason that hospital stay. The subjects will be contacted by research staff either in person or via phone to obtain consent. The PI will not solely determine eligibility or obtain consent.

This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. We will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential participants will be identified via Muscular Dystrophy Clinic patient list and clinic schedule review by a study team member who will screen patient for inclusion/exclusion criteria. Eligible patients will be approached by telephone or in private clinic room about participation in the study.

The objectives of this study are to generate evidence that improves the assessment of nutritional status in infants with CKD and ESKD, to differentiate malnutrition from fluid imbalance, and to inform individualized nutritional and medical interventions aimed at optimizing growth and developmental outcomes.THIS STUDY IS ENROLLING BY INVITATION ONLY - Eligible subjects will be identified through routine clinical care at Riley Hospital for Children by the nephrology, neonatology, and nutrition teams caring for infants with CKD or ESRD. On a weekly basis, research staff will review the inpatient nephrology census with the clinical team to screen infants under 12 months of age against inclusion and exclusion criteria, focusing on those in whom nutritional assessment is clinically challenging or who require dialysis. If an infant is identified as potentially eligible, the primary treating physician will first be approached to confirm that study participation is appropriate and safe; only with physician agreement will the family be contacted.

Individuals post lung transplant suffer from significantly reduced exercise capacity. Physical rehabilitation (such as that carried out in COLTT) has previously been shown to improve aerobic endurance and muscle strength, both of which are associated with improved survival. Unfortunately, there is very little known about the mechanisms behind these improvements. Near infra-red spectroscopy (NIRS) allows for the non-invasive assessment of oxyhemoglobin, deoxyhemoglobin (HHb), total hemoglobin (tHb) in the muscle vasculature during exercise, and has been widely used in a variety of clinical conditions. Therefore, we plan to test if rehabilitation improves muscle oxygenation in patients post lung transplant. We plan on non-invasively assessing muscle oxygenation using near infrared spectroscopy (NIRS) in patients after lung transplant. Specifically, patients will have their muscle oxygenation measured during a 6 minute walk test and sit-to-stand test before and after a ~4 week exercise program they already complete as standard of care.THIS STUDY IS ENROLLING BY INVITATION ONLY - This study is only enrolling patients who have been referred to COLTT after lung transplant. All study activities will be performed within the Center of Life for Thoracic Transplant (COLTT) rehabilitation center at IU Methodist Hospital. Patients will either be contacted by phone for recruitment/consenting, or this will be done in a private room on site.